Hemophilia A - Pipeline Review, H1 2017

  • ID: 4267375
  • Report
  • 151 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amarna Therapeutics BV
  • Catalyst Biosciences Inc
  • EpiVax Inc
  • Lentigen Technology Inc
  • Pangen Biotech Inc.
  • rEVO Biologics Inc
  • MORE
Hemophilia A - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H1 2017, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.

Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 6, 5, 1, 20, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amarna Therapeutics BV
  • Catalyst Biosciences Inc
  • EpiVax Inc
  • Lentigen Technology Inc
  • Pangen Biotech Inc.
  • rEVO Biologics Inc
  • MORE
Introduction

Hemophilia A - Overview

Hemophilia A - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hemophilia A - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hemophilia A - Companies Involved in Therapeutics Development

Alnylam Pharmaceuticals Inc

Amarna Therapeutics BV

Apitope International NV

Bayer AG

BioMarin Pharmaceutical Inc

Bioverativ Inc

Catalyst Biosciences Inc

Chugai Pharmaceutical Co Ltd

CSL Ltd

DBV Technologies SA

Dimension Therapeutics Inc

Emergent BioSolutions Inc

EpiVax Inc

Expression Therapeutics LLC

Green Cross Corp

Idogen AB

Immusoft Corp

Lentigen Technology Inc

mAbxience SA

Novo Nordisk A/S

OPKO Biologics Ltd

Pangen Biotech Inc.

Pfizer Inc

Pharming Group NV

Promethera Biosciences SA

rEVO Biologics Inc

Sangamo Therapeutics Inc

Shire Plc

SK Chemicals Co Ltd

Spark Therapeutics Inc

UniQure NV

XL-protein GmbH

Hemophilia A - Drug Profiles

antihemophilic factor (recombinant) - Drug Profile

antihemophilic factor (recombinant) - Drug Profile

antihemophilic factor (recombinant) - Drug Profile

antihemophilic factor (recombinant) - Drug Profile

antihemophilic factor (recombinant) - Drug Profile

antihemophilic factor (recombinant) - Drug Profile

antihemophilic factor (recombinant) biosimilar - Drug Profile

antihemophilic factor (recombinant) biosimilar - Drug Profile

antihemophilic factor (recombinant) biosimilar - Drug Profile

antihemophilic factor (recombinant), PEGylated - Drug Profile

antihemophilic factor (recombinant), pegylated - Drug Profile

antihemophilic factor (recombinant), porcine sequence - Drug Profile

antihemophilic factor (recombinant), single chain - Drug Profile

ATXF-8117 - Drug Profile

BAX-888 - Drug Profile

BAY-1093884 - Drug Profile

BIVV-001 - Drug Profile

BMN-270 - Drug Profile

Cell Therapy to Target Coagulation Factor VIII for Hemophilia A - Drug Profile

coagulation factor VIIa (recombinant) - Drug Profile

concizumab - Drug Profile

CSL-689 - Drug Profile

damoctocog alfa pegol - Drug Profile

Deimmunized FVIII - Drug Profile

DTX-201 - Drug Profile

emicizumab - Drug Profile

ET-3 - Drug Profile

fitusiran - Drug Profile

Gene Therapy for Hematological Disorders - Drug Profile

Gene Therapy for Hemophilia A - Drug Profile

Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile

Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile

HepaStem - Drug Profile

IN-3012 - Drug Profile

Kovaltry - Drug Profile

LG-889 - Drug Profile

LR-769 - Drug Profile

marzeptacog alfa - Drug Profile

MG-1113A - Drug Profile

MOD-5014 - Drug Profile

Monoclonal Antibody for Hemophilia A - Drug Profile

PBB-8-IN - Drug Profile

PF-06741086 - Drug Profile

Recombinant Factor VIII Replacement for Hemophilia A - Drug Profile

Recombinant Protein to Inhibit Coagulation Factor XIV for Hemophilia A and Hemophilia B - Drug Profile

Recombinant Protein to Replace Coagulation Factor VIII for Hemophilia A - Drug Profile

Recombinant Proteins for Hemophilia A - Drug Profile

SB-525 - Drug Profile

SEL-201 - Drug Profile

SHP-656 - Drug Profile

SPK-8011 - Drug Profile

SVF-VIIa - Drug Profile

Hemophilia A - Dormant Projects

Hemophilia A - Discontinued Products

Hemophilia A - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Hemophilia A, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1 2017 (Contd..2), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Hemophilia A - Pipeline by Alnylam Pharmaceuticals Inc, H1

Hemophilia A - Pipeline by Amarna Therapeutics BV, H1

Hemophilia A - Pipeline by Apitope International NV, H1

Hemophilia A - Pipeline by Bayer AG, H1

Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc, H1

Hemophilia A - Pipeline by Bioverativ Inc, H1

Hemophilia A - Pipeline by Catalyst Biosciences Inc, H1

Hemophilia A - Pipeline by Chugai Pharmaceutical Co Ltd, H1

Hemophilia A - Pipeline by CSL Ltd, H1

Hemophilia A - Pipeline by DBV Technologies SA, H1

Hemophilia A - Pipeline by Dimension Therapeutics Inc, H1

Hemophilia A - Pipeline by Emergent BioSolutions Inc, H1

Hemophilia A - Pipeline by EpiVax Inc, H1

Hemophilia A - Pipeline by Expression Therapeutics LLC, H1

Hemophilia A - Pipeline by Green Cross Corp, H1

Hemophilia A - Pipeline by Idogen AB, H1

Hemophilia A - Pipeline by Immusoft Corp, H1

Hemophilia A - Pipeline by Lentigen Technology Inc, H1

Hemophilia A - Pipeline by mAbxience SA, H1

Hemophilia A - Pipeline by Novo Nordisk A/S, H1

Hemophilia A - Pipeline by OPKO Biologics Ltd, H1

Hemophilia A - Pipeline by Pangen Biotech Inc., H1

Hemophilia A - Pipeline by Pfizer Inc, H1

Hemophilia A - Pipeline by Pharming Group NV, H1

Hemophilia A - Pipeline by Promethera Biosciences SA, H1

Hemophilia A - Pipeline by rEVO Biologics Inc, H1

Hemophilia A - Pipeline by Sangamo Therapeutics Inc, H1

Hemophilia A - Pipeline by Shire Plc, H1

Hemophilia A - Pipeline by SK Chemicals Co Ltd, H1

Hemophilia A - Pipeline by Spark Therapeutics Inc, H1

Hemophilia A - Pipeline by UniQure NV, H1

Hemophilia A - Pipeline by XL-protein GmbH, H1

Hemophilia A - Dormant Projects, H1

Hemophilia A - Dormant Projects, H1 2017 (Contd..1), H1

Hemophilia A - Discontinued Products, H1

List of Figures:

Number of Products under Development for Hemophilia A, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alnylam Pharmaceuticals Inc
  • Amarna Therapeutics BV
  • Apitope International NV
  • Bayer AG
  • BioMarin Pharmaceutical Inc
  • Bioverativ Inc
  • Catalyst Biosciences Inc
  • Chugai Pharmaceutical Co Ltd
  • CSL Ltd
  • DBV Technologies SA
  • Dimension Therapeutics Inc
  • Emergent BioSolutions Inc
  • EpiVax Inc
  • Expression Therapeutics LLC
  • Green Cross Corp
  • Idogen AB
  • Immusoft Corp
  • Lentigen Technology Inc
  • mAbxience SA
  • Novo Nordisk A/S
  • OPKO Biologics Ltd
  • Pangen Biotech Inc.
  • Pfizer Inc
  • Pharming Group NV
  • Promethera Biosciences SA
  • rEVO Biologics Inc
  • Sangamo Therapeutics Inc
  • Shire Plc
  • SK Chemicals Co Ltd
  • Spark Therapeutics Inc
  • UniQure NV
  • XL-protein GmbH
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll